<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>245-GEMFIBROZIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GEMFIBROZIL" rxcui="4719">
<ATC code="C10AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DASABUVIR" rxcui="1597381">
<ATC code="J05AX16" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of the dasabuvir by the gemfibrozil</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>245-GEMFIBROZIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GEMFIBROZIL" rxcui="4719">
<ATC code="C10AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ENZALUTAMIDE" rxcui="130729">
<ATC code="L02BB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the active fraction of the enzalutamide</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reduce the dose of enzalutamide by half when administered with the gemfibrozil.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>245-GEMFIBROZIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GEMFIBROZIL" rxcui="4719">
<ATC code="C10AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIOGLITAZONE" rxcui="33738">
<ATC code="A10BG03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the glitazone due to decrease of its hepatic metabolism by the gemfibrozil</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, strict clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>245-GEMFIBROZIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GEMFIBROZIL" rxcui="4719">
<ATC code="C10AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of severe hypoglycemia, even coma, due to substantial increase of the plasma concentrations of repaglinide by the gemfiborzil</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
